Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.89)
# 658
Out of 5,124 analysts
215
Total ratings
57.48%
Success rate
7.54%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Neutral | $305 → $315 | $327.31 | -3.76% | 18 | Nov 6, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $100 → $112 | $100.59 | +11.34% | 2 | Oct 31, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $925 → $985 | $1,074.68 | -8.34% | 14 | Oct 31, 2025 | |
| GILD Gilead Sciences | Reiterates: Overweight | $135 | $122.74 | +9.99% | 16 | Oct 31, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $678 → $740 | $771.87 | -4.13% | 21 | Oct 29, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $245 → $250 | $228.49 | +9.41% | 18 | Oct 9, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $485 | $453.36 | +6.98% | 4 | Aug 5, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $55 | $53.94 | +1.97% | 16 | Apr 23, 2025 | |
| PFE Pfizer | Initiates: Neutral | $24 | $24.90 | -3.61% | 15 | Apr 22, 2025 | |
| PCVX Vaxcyte | Initiates: Overweight | n/a | $46.14 | - | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $85 | $105.26 | -19.25% | 11 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $141.83 | +16.34% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $38.21 | -47.66% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $175.99 | +2.28% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $60 | $13.08 | +358.72% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $0.70 | +328.51% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.32 | +581.82% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $63.54 | +49.51% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $9.30 | +115.05% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $65.20 | +11.96% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $1.56 | +669.23% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $3.10 | -51.61% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $0.10 | +2,150.00% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $159.36 | +138.45% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $98.77 | -16.98% | 5 | Jan 16, 2019 |
Amgen
Nov 6, 2025
Maintains: Neutral
Price Target: $305 → $315
Current: $327.31
Upside: -3.76%
Nuvalent
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $112
Current: $100.59
Upside: +11.34%
Eli Lilly and Company
Oct 31, 2025
Maintains: Overweight
Price Target: $925 → $985
Current: $1,074.68
Upside: -8.34%
Gilead Sciences
Oct 31, 2025
Reiterates: Overweight
Price Target: $135
Current: $122.74
Upside: +9.99%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Overweight
Price Target: $678 → $740
Current: $771.87
Upside: -4.13%
AbbVie
Oct 9, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $228.49
Upside: +9.41%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Overweight
Price Target: $535 → $485
Current: $453.36
Upside: +6.98%
Bristol-Myers Squibb Company
Apr 23, 2025
Reiterates: Neutral
Price Target: $55
Current: $53.94
Upside: +1.97%
Pfizer
Apr 22, 2025
Initiates: Neutral
Price Target: $24
Current: $24.90
Upside: -3.61%
Vaxcyte
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $46.14
Upside: -
Apr 22, 2025
Initiates: Neutral
Price Target: $85
Current: $105.26
Upside: -19.25%
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $141.83
Upside: +16.34%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $38.21
Upside: -47.66%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $175.99
Upside: +2.28%
Aug 14, 2024
Maintains: Overweight
Price Target: $200 → $60
Current: $13.08
Upside: +358.72%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $0.70
Upside: +328.51%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.32
Upside: +581.82%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $63.54
Upside: +49.51%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $9.30
Upside: +115.05%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $65.20
Upside: +11.96%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $1.56
Upside: +669.23%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $3.10
Upside: -51.61%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $0.10
Upside: +2,150.00%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $159.36
Upside: +138.45%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $98.77
Upside: -16.98%